# Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

> **NCT05311943** · PHASE3 · UNKNOWN · sponsor: **Shenzhen Second People's Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Olverembatinib
- Chronic Myeloid Leukemia, Chronic Phase
- Tyrosine Kinase Inhibitors

## Interventions

- **DRUG:** olverembatinib

## Key facts

- **NCT ID:** NCT05311943
- **Lead sponsor:** Shenzhen Second People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05311943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05311943, "Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05311943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*